6 months ago
LLY
AnalystsEmily FieldEmily Field's Stock Forecasts
AnalystsEmily Field
Sectors:
Industries:
Analyst Ranking
Top 34%
#1866 out of 5549 analysts
Average Return
+10.88%
Win Rate
77%10 out of 13
Risk vs Reward
Poor
Good
Emily Field's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Eli Lilly & CoLLY | +38.92% | $988.87 | $1,373.70 | 2026-05-05 - 2026-10-29 | Strong Buy |
Eli Lilly & CoLLY | +36.07% | $1,009.52 | $1,373.70 | 2026-02-20 - 2026-10-29 | Strong Buy |
Abbvie IncABBV | +29.35% | $224.81 | $290.79 | 2026-02-20 - 2026-10-29 | Strong Buy |
Argenx SeARGX | +27.02% | $295.58 | $375.44 | 2021-10-19 - 2022-10-18 | Strong Buy |
Merck & Co IncMRK | +19.69% | $122.26 | $146.33 | 2026-02-20 - 2026-10-29 | Strong Buy |
Emily Field Analyst Color
Get additional color on Emily Field's coverage of popular stocks
8 months ago
MRK
8 months ago
LLY
Emily Field's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Biogen IncBIIB | 3 | Hold | $230.00 | -7.87% | Maintains | 2 days ago |
Merck & Co IncMRK | 3 | Strong Buy | $180.00 | +23.01% | Maintains | 4 days ago |
Amgen IncAMGN | 4 | Hold | $400.00 | -13.18% | Maintains | 9 days ago |
Abbvie IncABBV | 3 | Strong Buy | $325.00 | +11.76% | Maintains | 9 days ago |
Helus Pharma IncHELP | 1 | Strong Buy | $35.00 | +226.80% | Initiates Coverage On | a month ago |
Cytokinetics IncCYTK | 1 | Strong Buy | $110.00 | +73.75% | Maintains | 3 months ago |
Gilead Sciences IncGILD | 2 | Hold | $145.00 | -12.44% | Maintains | 3 months ago |
Eli Lilly & CoLLY | 2 | Strong Buy | $1,400.00 | +1.91% | Maintains | 6 months ago |
Pfizer IncPFE | 1 | Strong Sell | $25.00 | -16.53% | Initiates Coverage On | 8 months ago |
Bristol Myers Squibb CoBMY | 1 | Strong Buy | $75.00 | +22.17% | Initiates Coverage On | 8 months ago |
Novo Nordisk A SNVO | 1 | Hold | N/A | N/A | Downgrades | a year ago |
Gsk PLCGSK | 1 | Hold | N/A | N/A | Upgrades | 5 years ago |
Argenx SeARGX | 1 | Strong Buy | N/A | N/A | Upgrades | 5 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.